H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

Scotiabank initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 price target Maximize Your Portfolio with Data ...

VKTX stock opened at $30.48 on Thursday. Viking Therapeutics has a fifty-two week low of $28.64 and a fifty-two week high of $99.41. The business’s 50-day moving average is $37.97 and its two ...

In trading on Thursday, shares of Viking Therapeutics Inc (Symbol: VKTX) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $28.81 per share.

Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (LSE:0VQA) with a Sector Outperform recommendation. There are 784 funds or institutions reporting ...

View the VKTX option chain and compare options of Viking Therapeutics Inc stock. Analyze the various options available, including call options (the right to buy) and put options (the right to sell ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Minnesota Vikings are at a crossroads at the most important position in the sport: quarterback. The club managed to win 14 games in the regular season and make the playoffs large in part due ...

It's officially time for offseason speculation as the Minnesota Vikings will have some decision to make in 2025. Among them are players who they may deem dispensable this offseason. One of those ...